Adjuvant interferon-alpha in malignant melanoma: Current status

Cancer Treatment Reviews

Volumn 26, Issue 2, 2000, Pages 81-89

  Hancock, B W ^a   Harris, S ^a   Wheatley, K ^b   Gore, M ^c  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Interferon alpha; Malignant melanoma

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CYTOTOXIC AGENT; DACARBAZINE; GANGLIOSIDE; LEVAMISOLE; MONOCLONAL ANTIBODY; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; TRANSFER FACTOR; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DOSE CALCULATION; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; MELANOMA; META ANALYSIS; MYALGIA; NAUSEA; REVIEW; TASTE DISORDER; VOMITING; WEIGHT REDUCTION;

EID: 0034109334     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0163     Document Type: Review

References (45)

1. Meyskens F. L. Jr, Kopecky K. J., Taylor C. W., Noyes R. D., Tuthill R. J., Hersh E. M., Feun L. G., Doroshow J. H., Flaherty L. E., Sondak V. K. Randomised trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Nat Cancer Inst. 87:1995;1710-1713.
2. Creagan E. T., Ahmann D. L., Green S. J., Long H. J., Rubin J., Schutt A. J., Dziewanowski Z. E. Phase II study of recombinant leukocyte A interferon (r-IFN A) in disseminated malignant melanoma. Cancer. 54:1984;2844-2849.
3. Creagan E. T., Ahmann D. L., Green S. J., Long H. J., Frytak S., O'Fallon J. R., Itri L. M. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol. 2:1984;1002-1005.
4. Creagan E. T., Ahmann D. L., Frytak S., Long H. J., Chang M. N., Itri L. M. Three consecutive phase II-studies of recombinant interferon alpha-2a in advanced malignant melanoma. Cancer. 59:1987;638-646.
5. Legha S. S., Papadopoulos N. E., Plager C., Ring S., Chawla S. P., Evans L. M., Benjamin R. S. Clinical evaluation of recombinant interferon alpha-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol. 5:1987;1240-1246.
6. Hersey P., Hasic E., MacDonald M., Edwards A., Spurling A., Coates A. S., Milton G. W., McCarthy W. H. Effects of recombinant leucocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer. 51:1985;815-826.
7. Neefe J. R., Legha S. S., Markowitz A., Salmon S., Meyskens F., Groopman J., Campion M., Evans L. Phase II study of recombinant alpha-interferon in malignant melanoma. Am J Clin Oncol. 13:1990;472-476.
8. Dorval T., Palangie T., Jouve M., Garcia-Giralt E., Israel L., Falcoff E., Schwab D., Pouillart P. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer. 58:1986;215-218.
9. Mughal J. E., Robinson W. A., Thomas M. R., Spiegel R. J. Role of recombinant interferon-alpha-2 in treatment of advanced malignant melanoma. Proc Am Soc Clin Oncol. 7:1988;250.
10. Mickiewicz E., Estevez R., Rao F., Breier S., Balbiani L., Cabalar E., Cazap E., Cassini J., Gerchunoff M., Temperley G., Caparros C. Interferon-alpha-2b (rIFN-alpha-2b) alone or in combination with DTIC in metastatic melanoma (MM). Compiled Data. Proc Am Soc Clin Oncol. 9:1990;281.
11. Kirkwood J. M., Ernstoff M. S., Davis C. A., Reiss M., Ferraresi R., Rudnick S. A. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 103:1985;32-36.
12. Robinson W. A., Mughal T. I., Thomas M. R., Johnson M., Spiegel R. J. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology. 172:1986;275-282.
13. Elsasser-Beile U., Drees N., Neumann H. A., Schopf E. Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma. J Cancer Res Clin Oncol. 113:1987;273-278.
14. Steiner A., Wolf C., Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol. 113:1987;459-465.
15. Coates A., Rallings M., Hersey P., Swanson C. Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res. 6:1986;1-4.
16. Sheridan E., Hancock B. W. Systemic treatment of metastatic malignant melanoma. Kirkham N., Cotton D. W.K., Lallemand R. C., White J. E., Rosin R. D. Diagnosis and Management of Melanoma in Clinical Practice. 1992;135-156 Springer-Verlag, London.
17. Legha S. S. The role of interferon alfa in the treatment of metastatic melanoma. Sem Oncol. 24:1997;24-31.
18. de Takats P. G., Williams M. V., Hawkins R. Adjuvant therapy for melanoma: how should we respond to high-dose interferon? Cancer. 77:1998;1287-1293.
19. Cascinelli N., Bufalino R., Morabito A., MacKie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 343:1994;913-914.
20. Cascinelli N. Evaluation of efficacy of adjuvant rIFNα 2 α in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol. 14:1995;410.
21. Cascinelli, N. Data presented at 3rd International Conference on Adjuvant Therapy of Malignant Melanoma. London, 1999.
22. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J Clin Oncol. 14:1996;7-17.
23. Kirkwood J. M., Ibrahim J., Sondak V., Ernstoff M., Flaherty L., Smith T., Richards J., Rao U., Blum R. Preliminary analysis of the E1690/S9111/C9190 Intergroup postoperative adjuvant trial of high- and low-dose IFNα2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma. Proc Am Soc Clin Oncol. 18:1999;537a.
24. Grob J. J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., Souterand P., Sassolas B., Cesarini J-P., Lionnet S., Lok C., Chastang C., Bonerandi J. J. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1-5 mm without clinically detectable node metastases. Lancet. 351:1998;1905-1910.
25. Pehamberger H., Sayer H. P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Auböck J., Fritsch P., Kerl H., Wolff K. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 16:1998;1425-1429.
26. Creagan E. T., Dalton R. J., Ahmann D. L., Jung Sin-Ho, Morton R. F., Langdon R. M. Jr, Kugler J., Rodrigue L. J. Randomised, surgical adjuvant trial of recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 13:1995;2776-2783.
27. Kleeberg U. R., Bröcker E. B., Lejeune F., Chartier C., Egger C., Marsden J., Ruiter D., Suciu S. Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (>3 mm) or regional lymphnode metastasis (EORTC 18871). The European Journal of Cancer. 35, Supplement 4:1999;S82.
28. Personal communication Cornbleet.
29. Cole B. F., Gelber R. D., Kirkwood J. M., Goldhirsch A., Barylak E., Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Co-operative Oncology Group study. J Clin Oncol. 14:1996;2666-2673.
30. Hillner B. E., Kirkwood J. M., Atkins M. B., Johnson E. R., Smith T. J. Economic analysis of adjuvant interferon-alfa 2b in high risk melanoma based on projections from Eastern Co-operative Oncology Group 1684. J Clin Oncol. 15:1997;2351-2358.
31. Terry W. D. Immunotherapy of malignant melanoma. N Engl J Med. 303:1980;1174-1175.
32. Czarnetzki B. M., Macher E., Suciu S., Thomas D., Steerenberg P. A., Rumke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC PROTOCOL 18781). Eur J Cancer. 29A:1993;1237-1242.
33. Paterson A. H., Willans D., Jerry L. M., Hanson J., McPherson T. A. Adjuvant BCG immunotherapy of malignant melanoma. Can Med Assoc J. 131:1984;744-748.
34. Fisher R. J., Terry W. D., Hodes R. J., Rosenberg S. A., Makuch R., Gordon H. G., Fisher S. G. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomised clinical trial. Surg Clin North Am. 61:1981;1267-1277.
35. Veronesi U., Adamus J., Aubert C., Bajetta E., Beretta G., Bonadonna G., Bufalino R., Cascinelli N., Cocconi G., Durand J., De Marsillac J., Ikonopisov R. L., Kiss B., Lejeune F., MacKie R., Madej G., Mulder H., Mechl Z., Milton G. W., Morabito A., Peter H., Priario J., Paul E., Rumke P., Sertoli R., Tomin R. A randomised trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 307:1982;913-916.
36. Balch C. M., Smalley R. V., Bartolucci A. A., Burns D., Presant C., Durant J. R. A randomised prospective clinical trial of adjuvant C.parvum immunotherapy in 260 patients with clinically localised melanoma (stage I). Cancer. 49:1982;1079-1084.
37. Bukowski R. M., Deodhar S., Hewlett J. S., Greenstreet R. Randomised controlled trial of transfer factor in stage II malignant melanoma. Cancer. 51:1983;269-272.
38. Quirt I. C., Shelley W. E., Pater J. L., Bodurtha A. J., McCulloch P. B., McPherson T. A., Paterson A. H., Prentice R., Silver H. K., Willan A. R. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the national cancer institute of Canada clinical trials group. J Clin Oncol. 9:1991;729-735.
39. Spitler L. E. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol. 9:1991;736-740.
40. Chan D., Morton D. L. Active Immunotherapy with allogeneic tumour cell vaccines: Present status. Seminars in Oncology. 25:1998;611-622.
41. Meisenberg B. R., Ross M., Vredenburgh J. J., Jones R., Shpall E. J., Seigler H. F., Coniglio D. M., Wu K., Peters W. P. Randomised trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high risk, multinode positive malignant melanoma. J Natl Cancer Inst. 85:1993;1080-1085.
42. Livingstone P. O., Wong G. Y. C., Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 12:1994;1036-1044.
43. Balch C. M., Reintgen D. S., Kirkwood J. M., Houghton A., Peter L., Ang K. K. Cutaneous melanoma. De Vita V.T. Hellman S., Rosenberg S. A. Cancer: Principles and Practice of Oncology. 1997;1947-1994 Lippincott-Raven Publishers, Philadelphia.
44. Personal communication, Gore, M.
45. Selby P., Gillis C., Haward R. Benefits from specialised cancer care. Lancet. 348:1996;313-318.